In the pipeline: Epratuzumab
Today's featured lymphoma treatment in the pipeline is the monoclonal antibody epratuzumab.
Name: Epratuzumab (marketed as LymphoCIDE)
Class: Anti-CD22 humanized monoclonal antibody
Type: Biological therapy
FDA to date: Orphan drug status; fast track designation (for lupus)
Manufacturer: Immunomedics Inc
Indications: Diffuse large b-cell lymphoma, follicular lymphoma, acute lymphblastic leukemia.
A few words: Epratuzumab targets cells expressing CD22 cell-surface receptors and is being investigated as part of combination chemotherapy, namely in an established regimen (ER-CHOP) against DLBCL. It has also been studied—with impressive results—as an agent of radioimmunotherapy (90Y-epratuzumab) in a small trial in patients with relapsed/refractory non-Hodgkin lymphoma and indolent lymphomas. The drug is also being explored as a treatment for autoimmune disorders such as lupus. Phase III trials are underway for all indications.
Click here to see clinical trials involving epratuzumab
Related studies
Morschhauser F et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol. 2010 Aug 10;28(23):3709-16. Epub 2010 Jul 12
Micallef IN et al. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer. 2006 Dec 15;107(12):2826-32.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
